Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Actuarialon May 20, 2021 4:27pm
255 Views
Post# 33242296

RE:RE:RE:15$ US Target reiterated today as well

RE:RE:RE:15$ US Target reiterated today as wellHey Johnny, you are too emotional on this case. We need to be objective on each clinical trial results. If it contains something like "statistical significant", I know it is promising. However, it says "modest" and 33% in the paper, I am not impressed. I will keep holding my shares waiting for the CAR-T cell. And obviously, it will be a long wait. GLTA.
JohnnyYeg wrote: Getting so annoyed with people who say "oh but I'm long on ONC" after exploiting any opportunity to bash or create an air of disillusionment. But thankfully with all bull boards out there you are given the functionality to block them. Cannot. Be. Bothered. With. Negativity. Which is why I have left Yahoo Finance altogether. Miss only a few posters on there.


<< Previous
Bullboard Posts
Next >>